# Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

> **NCT04139018** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 27 (actual)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia

## Interventions

- **DRUG:** Timolol Gel
- **DRUG:** Placebo Gel

## Key facts

- **NCT ID:** NCT04139018
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-20
- **Primary completion:** 2020-05-20
- **Final completion:** 2020-05-20
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04139018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04139018, "Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04139018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*